search button
Open Access

MicroRNA‑490‑3p and ‑490‑5p in carcinogenesis: Separate or the same goal? (Review)

  • Authors:
    • Yin Li
    • Dongmei Tian
    • Hao Chen
    • Yuanting Cai
    • Sang Chen
    • Shiwei Duan

  • View Affiliations

  • Published online on: July 22, 2021     https://doi.org/10.3892/ol.2021.12939
  • Article Number: 678

  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

MicroRNA (miR)‑490‑3p and miR‑490‑5p, located on chromosome 7q33, are two independent mature products of miR‑490 exerting distinct effects on tumor progression. miR‑490‑3p and miR‑490‑5p possess antitumor properties. miR‑490‑3p dysfunction has been associated with malignancies including colorectal cancer, while the abnormal function of miR‑490‑5p has been more considerably associated with bladder cancer (for example). At present, there are 30 and 11 target genes of miR‑490‑3p and miR‑490‑5p, respectively, that have been experimentally verified, of which the cyclin D1 (CCND1) gene is a common target. Through these target genes, miR‑490‑3p and miR‑490‑5p are involved in 7 and 3 signaling pathways, respectively, of which only 2 are shared regulatory signaling pathways. The present review introduces two competing endogenous RNA (ceRNA) regulatory networks centered on miR‑490‑3p and miR‑490‑5p. These networks may be important promoters of tumor cell proliferation, invasiveness, metastatic potential and apoptosis. Unlike miR‑490‑5p, miR‑490‑3p plays a unique role in promoting cancer. However, both are promising molecular markers for early cancer diagnosis and prognosis. In addition, miR‑490‑3p was also found to be associated with the chemical resistance of cisplatin and paclitaxel. The present review focuses on the abnormal expression of miR‑490‑3p and miR‑490‑5p in different tumor types, and their complex ceRNA regulatory networks. The clinical value of miR‑490‑3p and miR‑490‑5p in cancer diagnosis, prognosis and treatment is also clarified, and an explanation for the opposing effects of miR‑490‑3p in tumor research is provided.
View Figures
View References

Related Articles

Journal Cover

September-2021
Volume 22 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li Y, Tian D, Chen H, Cai Y, Chen S and Duan S: MicroRNA‑490‑3p and ‑490‑5p in carcinogenesis: Separate or the same goal? (Review). Oncol Lett 22: 678, 2021
APA
Li, Y., Tian, D., Chen, H., Cai, Y., Chen, S., & Duan, S. (2021). MicroRNA‑490‑3p and ‑490‑5p in carcinogenesis: Separate or the same goal? (Review). Oncology Letters, 22, 678. https://doi.org/10.3892/ol.2021.12939
MLA
Li, Y., Tian, D., Chen, H., Cai, Y., Chen, S., Duan, S."MicroRNA‑490‑3p and ‑490‑5p in carcinogenesis: Separate or the same goal? (Review)". Oncology Letters 22.3 (2021): 678.
Chicago
Li, Y., Tian, D., Chen, H., Cai, Y., Chen, S., Duan, S."MicroRNA‑490‑3p and ‑490‑5p in carcinogenesis: Separate or the same goal? (Review)". Oncology Letters 22, no. 3 (2021): 678. https://doi.org/10.3892/ol.2021.12939